The Cancer Letter

Inside information on cancer research and drug development

Vol.
34
No.
11
March 21, 2008Mar 21, 2008
Free
DOWNLOAD THE PDF

ODAC Meeting: Further Restrictions Likely On ESA Use; Changes Advocated by ODAC May Cut Market By 40-50 Percent.

ODAC Member Critical Of Amgen For Price Incentives.

Amgen, J&J Defend ESA Indications.

ODAC Recommends Approval Of Nplate For Thrombocytopenia.

Funding Opportunities: HHMI Commits $300M To Support Early Career Scientists.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account